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mtDNA variations often result in bioenergetic dysfunction inducing a metabolic switch
toward glycolysis resulting in an unbalanced pH homeostasis. In hypoxic cells,
expression of the tumor-associated carbonic anhydrase IX (CAIX) is enhanced tomaintain
cellular pH homeostasis. We hypothesized that cells with a dysfunctional oxidative
phosphorylation machinery display elevated CAIX expression levels. Increased glycolysis
was observed for cytoplasmic 143B mutant hybrid (m.3243A>G, >94.5%) cells (p <
0.05) and 143B mitochondrial DNA (mtDNA) depleted cells (p < 0.05). Upon hypoxia
(0.2%, 16 h), genetic or pharmacological oxidative phosphorylation (OXPHOS) inhibition
resulted in decreased CAIX (p < 0.05), vascular endothelial growth factor (VEGF) and
hypoxia-inducible factor 1-alpha (HIF-1α) expression levels. Reactive oxygen species
(ROS) and prolyl-hydroxylase 2 (PHD2) levels could not explain these observations. In
vivo, tumor take (>500 mm3) took longer for mutant hybrid xenografts, but growth
rates were comparable with control tumors upon establishment. Previously, it has been
shown that HIF-1α is responsible for tumor establishment. In agreement, we found that
HIF-1α expression levels and the pimonidazole-positive hypoxic fraction were reduced
for the mutant hybrid xenografts. Our results demonstrate that OXPHOS dysfunction
leads to a decreased HIF-1α stabilization and subsequently to a reduced expression
of its downstream targets and hypoxic fraction in vivo. In contrast, hypoxia-inducible
factor 2-alpha (HIF-2α) expression levels in these xenografts were enhanced. Inhibition
of mitochondrial function is therefore an interesting approach to increase therapeutic
efficacy in hypoxic tumors.
Keywords: mtDNA, mitochondria, OXPHOS, CAIX, HIF-1α, Metformin
INTRODUCTION
As the tumor microenvironment is a heterogeneous and dynamic entity, cells within a tumor
have different gene expression profiles, metabolism and oxygen supply. The lack of nutrient and
oxygen supply is associated with two main characteristics of a malignancy, namely bioenergetics
and angiogenesis (1). The adaptation of cancer cells to hypoxia, the low oxygen regions within
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a tumor and its metabolic consequences, is critical for tumor
progression. Tumors cells in a hypoxic tumor microenvironment
have often the capability to alter their metabolism and favor
metabolic pathways, which are less dependent on oxygen, to
meet their energy demand. Hypoxic tumor cells often produce
large amount of acids due to their increase in glycolysis
and have a decreased extracellular pH (2–4). One important
family of proteins involved in tumor pH maintenance are
carbonic anhydrases (CA) (5). The membrane bound zinc-
metallo-enzyme CAIX is capable of re-hydrating CO2 into
bicarbonate (HCO−3 ) and a proton (H
+) upon passive CO2
diffusion out of the cell. HCO−3 will subsequently re-enter the
cell in order to neutralize the intracellular pH. The remaining
proton acidifies the extracellular environment contributing to
the worse prognosis in cancer patients (6, 7). High CAIX
expression results in a higher risk of locoregional failure,
disease progression and metastases development in cancer
patients (8). In hypoxic tumors, CAIX expression is found
to be upregulated through transcriptional activation upon
interaction of hypoxia inducible factor-1α (HIF-1α) with the
hypoxia response element (HRE) identified in its promotor
region (9). In addition, the transport of lactate into the
microenvironment via monocarboxylate transporter 4 (MCT-
4) leads to a further increase in extracellular acidification. The
role of dysfunctional mitochondria in these mechanisms is of
interest, as it has been suggested that dysfunction of the oxidative
phosphorylation machinery contributes to tumoral metabolic
reprogramming (10, 11).
During hypoxic stress, the low efficiency glycolytic pathway
is further upregulated and is mainly driven by HIF-1α. The
high rate of glycolysis, which persists in tumor cells even
under re-oxygenation, is associated with an increase in glucose
uptake and lactate release. Lactic acidosis is a symptom
often observed in patients with mitochondrial diseases such
as the myoclonic epilepsy with ragged-red fibers (MERFF)
syndrome (12). A cybrid model harboring a m.8344A>G
mutation, encoding for ND5 subunit of Complex I (CI),
corresponding to the MERFF phenotype in patients resulting in
CI dysfunction, displayed reduced levels of carbonic anhydrase
VIII (CAVIII) (13). Furthermore, it has been suggested that
CAVIII regulates cellular stress responses and could also play
a role in metabolism. CAVIII knockdown cells were found to
have a decreases glycolytic activity and increased cell death
under reduced glucose concentrations in vitro (14). These data
suggest that mitochondrial dysfunction leading to decreased
carbonic anhydrase expression levels could also be observed
for other CA forms. Here, we investigated if the membrane-
bound carbonic anhydrase IX (CAIX) was upregulated in





The parental and mtDNA depleted (rho-zero, ρ0) 143B
osteosarcoma cell lines were kindly provided by Dr. Valeria
Tiranti (Milan, Italy). Both cell lines were cultured in Gibco’s
Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal
bovine serum (FBS; Sigma-Aldrich). Culture medium of the
mtDNA depleted cells was supplemented with 150µg/ml
uridine (Acros Organics) and 100µg/ml bromodeoxyuridine
(Sigma-Aldrich). The parental and mtDNA depleted A549
(alveolar type-II carcinoma) cell lines were cultured in
DMEM supplemented with 25% FBS, vitamins, amino acids
(Sigma-Aldrich) and uridine (50µg/ml; Acros Organics).
mtDNA depletion was sustained by culturing cells in medium
supplemented with ethidium bromide (50 ng/ml; Sigma-
Aldrich). Fluorescent confocal imaging and quantitative PCR
were used to confirm mtDNA depletion at several time points
during the experiments. For confocal imaging, cells were stained
(45min) with MitoTracker R© Deep-Red FM and Picogreen
(Invitrogen) in D-PBS (GIBCO) according to the manufacturer’s
protocol. Subsequently, cells were washed twice with D-PBS and
visualized using a Leica AOBS confocal microscope. Overlays
were generated using Image J. Ratios of nDNA (B2M) and
mtDNA (D-Loop) were obtained by quantitative PCR in order
to determine the mtDNA copy numbers. DNA was isolated
using the gentra puregene kit (Qiagen). Quantitative PCR was
performed on the 7900HT Fast Real-Time PCR System (Applied
Biosystems). Gene abundances were detected using the SensiMix
SYBR R© HiRox kit (Bioline Reagents). The cycling conditions
were: 50◦C (2min), 95◦C (10 s), 40 cycles at 95◦C (15 s) and 60◦C
(1min). Primer sequences for B2M and D-Loop can be found
in Table S1.
Cytoplasmic Hybrids (Cybrids) and Quantification of
Mutant mtDNA Percentage
Cytoplasmic hybrids cell lines (cybrids) were generated as
previously described (15, 16). In short, cybrids were generated by
fusing themtDNA from patient fibroblasts withmtDNA depleted
143B cells. Two control cybrid cell lines were generated using
fibroblast mtDNA from healthy volunteers (kindly provided
by Dr. Hubertus Smeets, Maastricht, the Netherlands), while 2
mutant cybrid cell lines were created using fibroblasts harboring
the m.3243A>G mutation encoding for mitochondrial tRNA-
Leu(UUR) (MT-TL1) and responsible for the “mitochondrial
encephalomyopathy, lactic acidosis, and stroke-like episodes”
(MELAS) syndrome (17). Fibroblasts originated from two
independent patients harboring the m.3243A>G mutation,
resulted in two independent mutant cybrid cell lines, named
MELAS 1 and MELAS 2. All cell lines were cultured in
DMEM supplemented with 5% dialyzed serum (Invitrogen).
To determine the percentage of mtDNA harboring the MELAS
m.3243A>G mutation, the coding mtDNA sequence was
amplified using primer sequences found in Table S1. The PCR
amplification consisted of an initial denaturation at 94◦C (5min),
followed by 32 cycles at 92◦C (1min), 53◦C (1min), 72◦C
(45 s) and a final elongation at 72◦C (7min). A FAM-labeled
forward primer was added to the first PCR product, which was
subjected to an additional PCR cycle. Gel electrophoresis (2%
agarose) confirmed size of the PCR products. Fragments were
excised from the gel and digested (2.5 h at 37◦C) using a mix
of sterile water, digestion buffer and the restriction enzyme Hae
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III. Digestion products were purified using the QiaQuick PCR
Purification kit (Qiagen) and analyzed with ABI 3730 using a G5
filter. The primer sequences for fragment analysis can be found
in Table S1.
Metabolic Profiling
Metabolic profiles were generated using the Seahorse XF96
extracellular Flux analyzer (Agilent) according to manufacturer’s
guidelines (18). Cells were seeded at an optimized cell density
of 30.000 cells/well. Basal respiration rates were determined
as described previously (19). The glycolysis stress test was
performed by sequential addition of 10mM glucose, optimized
oligomycin concentration (2.5µM) and 0.1M 2-deoxyglucose
(2-DG) (Sigma-Aldrich).
OXPHOS Inhibition
Five hundred thousand cells of each cell line were seeded in
6 cm centimeter dishes. Cells were exposed to either normoxia
(20% O2) or hypoxia (0.2% O2) for 16 h simultaneously with
incubation of vehicle (0.02% DMSO), 5mM metformin (Sigma-
Aldrich) or 1µM rotenone (Sigma-aldrich). After 16 h, cells were
immediately put on ice and were washed with PBS prior to
protein or RNA isolation.
DNA Isolation, RNA Isolation and Quantitative PCR
Analysis
mRNA was extracted using the NucleoSpin RNA II kit
(Bioke) and reverse transcribed using the iScript cDNA
Synthesis Kit (BioRad). All procedures were according to
the manufacturers’ instructions. Quantitative RT-PCR was
performed in the ABI 7700 (Applied Biosystems) or 7900HT
Fast Real-Time PCR. Gene abundances were detected with
SYBR R© Green (Eurogentec). mRNA expression was either
normalized to 18S or Actin. Primer sequences can be found
in Table S1.
SDS-PAGE and Western Blotting
Cells were lysed and processed as described previously (20,
21). Antibodies used were M75 (1:40) (kindly provided by
Silvia Pastorekova, Institute of Virology, Slovak Academy of
Science, Bratislava, Slovak Republic) against CAIX, anti-HIF-
1α (1:250, BD transduction), anti-HIF-2α (1:1.000, NB100-
122, Novus biologicals) and anti-β-actin (1:200.000, MP
biomedicals). Proteins were visualized by the horseradish
peroxidase method (anti-mouse or anti-rabbit, both 1:2.000,
Cell Signaling) by using ECL prime western blotting detection
reagent (Amersham Corp) or ECL supersignal west pico
(Thermo Fisher). Complete Western Blots can be found in
Data Sheet 1.
Flow Cytometry
Formation of reactive oxygen species (ROS) was detected 16 h
after hypoxia or normoxia exposure. Cells were incubated with
20µM dihydrorhodamine-123 during the last hour of exposure.
ROS levels were determined in the propidium iodide (Sigma-
Aldrich) negative population by flow cytometry (BD FACS
Canto II).
Hypoxia Tolerance
Cells were seeded in 6 cm dishes, allowed to attach under
normoxic conditions overnight and exposed to hypoxic
conditions (0.2% O2) for 24, 48, or 72 h. After hypoxic exposure,
medium was replaced and cells were allowed to form colonies
under normoxia for 7 days. Colonies were quantified after
staining and fixation with 0.4% methylene blue in 70% ethanol.
A colony was defined as > 50 cells.
In vivo Experiments
In vivo Models
Control and mutant cybrid cells (1.5∗106) were resuspended in
Basement Membrane Matrix (MatrigelTM BD Biosciences) and
injected subcutaneously into the lateral flank of adult NMRI
nu/nu mice (28–30 g). Tumor growth was monitored until
reaching a volume of 1.2 cm3.
Immunohistochemisty
Frozen xenograft tumors were sectioned (5µm) and stained
for hypoxia (pimonidazole) and CAIX. Sections were
fixed using cold acetone, rehydrated in TBS with 0.2%
Tween-20 (TBS-T) and pre-incubated with 1% normal
goat serum (NGS) before exposing them to the primary
antibodies: FITC-conjugated IgG1 mouse monocolonal
anti-pimonidazole (1:150, clone 4.3.11.3, HP1-Plus Kit,
Bio-connect) and rabbit polyclonal anti-CAIX (1:1.000,
Novus biologicals). After washing with TBS-T, incubation
with the secondary antibody goat anti-rabbit Alexa 594
(1:500) (Invitrogen) was performed. Sections were mounted
using fluorescent mounting medium (DakoCytomation) and
digitally scanned using an Olympus BX51WI fluorescence
microscope with a Hamamatsu EM-CCD C9100 digital
camera, a motorized stage (Ludl Mac 2000) and a 10x
objective. Micromanager 1.4 software was used for automated
image acquisition. Image stitching was performed by using
ImageJ software.
Statistics
All statistical analyses were performed with GraphPad Prism
(GraphPad Software, version 5.03, 2009, California, USA).
Student’s t– test was used to determine the statistical significance
of differences between two independent groups of variables.
A p-value < 0.05 was considered significant.
RESULTS
In order to investigate if extreme changes in oxidative
phosphorylation (OXPHOS) capacity would lead to a change
in CAIX expression, we used 143B and A549 mitochondrial
DNA (mtDNA) depleted cancer cell lines (ρ0 cells) (Figure 1;
Figure S1). Both cell lines showed a substantial decrease of
mtDNA (Figure 1A, Figure S1A), which was confirmed by
the significant (p < 0.01) decrease in mtDNA copy number
(Figure 1B and Figure S1B). Hypoxia-induced CAIX expression
was decreased (p < 0.05) in the cells depleted from their
mtDNA, at both mRNA (Figure 1C, Figure S1C) and protein
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FIGURE 1 | Generation and characterization of a mtDNA depleted cell line. (A) Merged images of dsDNA staining (green) and mitochondria (red). (B) Percentage
mtDNA copy number. (C) CAIX mRNA expression upon hypoxia. (D) Representative Western blot of CAIX protein expression upon normoxia (–) or hypoxia (+). Data
represent the mean ± SEM of ≥3 biological repeats. *p < 0.05, **p < 0.01.
levels (Figure 1D, Figures S1D, S2) as compared to their
parental counterparts.
Our observations were extended to a second model, in which
mtDNA is not abolished but harbors a point mutation, the so-
called cytoplasmic hybrid or cybrid model. For this purpose,
the mtDNA depleted 143B osteosarcoma cell line was fused
with the cytoplasts of a fibroblast cell line from a MELAS
patient carrying a m.3243A>G mutation. The generated mutant
cybrid polyclonal cell line MELAS 1 had an average mutation
load of 96.80%, while the control cybrid clones contained 99.85
(control 1) and 99.65% (control 2) of the wild-type sequence. The
independently obtained MELAS 2 cells showed a mutation load
of 82.33% (Figure 2A). To further characterize the cybridmodels,
metabolic activity was investigated by assessing mitochondrial
respiration and glycolytic capacity. Basal respiration of the
MELAS 1 cells was significantly (p < 0.05) reduced compared to
the controls (Figure 2B and Figure S3), a functional consequence
that also was observed for not only the m.3243A>G mutation
but also for cybrids having a frameshift (m.3571insC/MT-
ND1) mutation (22). Where MELAS 1 cells were completely
dependent on glycolysis, since no glycolytic reserve capacity
could be observed (Figure 2B), MELAS 2 did display a glycolytic
reserve capacity with comparable levels to the control cell lines,
suggesting that the OXPHOS was still functional in these cells.
Baseline respiration and glycolysis was similar for both control
cybrid lines. Upon hypoxia, CAIXmRNA and protein expression
were reduced inMELAS 1 cells as compared to the control cybrid
cells (Figures 2C,D).
For MELAS 2 mutants, harboring a lower mutation
percentage, this effect was rescued (Figure S4) and therefore
these mutant cells were excluded from further experiments. A
MELAS mutation leads to a reduction in activity of Complex
I–IV of the oxidative phosphorylation chain (17). In order to
investigate if the observed effects from the genetic approach
could bemimicked by pharmacological inhibition, wild-type cells
were exposed to either metformin or rotenone, both complex
I (CI) inhibitors. Pharmacological CI inhibition resulted in
reduced CAIX mRNA and protein expression upon hypoxia
exposure in the 143B parental cells (rotenone p < 0.05) and
the control cybrid line (metformin and rotenone p < 0.05)
(Figures 3A,B). CAIX expression was not reduced for the A549
cells (Figure S1E). Additionally, mRNA expression levels for
carbonic anhydrase XII (CAXII), another hypoxia inducible
carbonic anhydrase (23), were upregulated for 143B mtDNA
depleted cells and cells harboring a m.3243A>Gmutation under
hypoxia, but not for cells exposed to the CI inhibitor rotenone
(Figure S5). Vascular endothelial growth factor (VEGF) mRNA
expression, another HIF-1α downstream target next to CAIX,
was also decreased (Figure 3C). HIF-1α protein expression upon
hypoxia was reduced for the parental lines and the control cybrid
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FIGURE 2 | Generation and characterization of the cybrid model and influence on CAIX expression. (A) Procedure to generate MELAS and control cybrid cell lines
(left) and percentage m.3243A>G mutated mtDNA in these cybrid lines (right). (B) Metabolic profiling of the cybrid lines, showing basal respiration (left) and glycolysis
stress test results (right). (C) CAIX mRNA expression upon hypoxia. (D) Representative Western blot of CAIX protein expression upon normoxia (–) or hypoxia (+).
Data represents mean + SEM of ≥3 independent biological repeats. *p < 0.05, **p < 0.01.
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FIGURE 3 | The influence of pharmacological CI inhibition on CAIX and other HIF-1α targets upon low oxygen levels. (A) CAIX mRNA expression upon hypoxia with or
without Metformin (5mM) or Rotenone (1µM). (B) Representative Western blot and quantification of CAIX protein expression upon normoxia (–) or hypoxia (+) with or
without Metformin (M, 5mM) or Rotenone (R, 1µM). (C) VEGF and (D) HIF-1α mRNA expression under hypoxia. (E) Representative Western blot and quantification of
HIF-1α protein expression upon normoxia (–) or hypoxia (+), combined with exposure of vehicle (–), metformin (M) or rotenone (R). Data represents the mean of ≥2
independent biological repeats + SEM. *p < 0.05.
line after exposure to metformin. HIF-1α mRNA expression was
not affected (Figure 3D), while HIF-1α protein expression was in
general low for MELAS 1 mutant cells (Figure 3E).
Prolyl-hydroxylase 2 (PHD2) is the main regulator of HIF-
1α stabilization (24–26). Therefore, we investigated if changes
in PHD2 expression could explain the observed reduction
in HIF-1α stabilization and expression of its downstream
targets. PHD2 mRNA expression was not changed upon genetic
imposed mitochondrial dysfunction (Figure 4A). Similarly,
mRNA expression of PHD1 and PHD3 did not alter (data not
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FIGURE 4 | HIF-1α regulators. (A) Normalized PHD2 mRNA expression and (B) Normalized ROS production upon mtDNA depletion (left) or mtDNA mutation (right)
under hypoxic conditions with or without OXPHOS CI inhibitors metformin (M) or rotenone (R). Data are normalized to either 143B (left) or ctrl 1 cybrid cell lines (right).
Data represents the mean of ≥2 independent biological repeats ± SEM.
shown). Another major contributor to HIF-1α stabilization is the
presence of ROS production (27, 28). Contradictory results have
been reported on the influence of mtDNA variations on ROS
production, which can be increased (17, 29) or decreased (30, 31).
Hypoxia-induced ROS production was slightly decreased (P =
0.0636) for the mtDNA depleted as compared to the parental
143B cells, while no differences were observed between the
cybrid cell lines (control vs. MELAS 1) (Figure 4B, Figure S6).
Additionally, pharmacological inhibition was not able to change
ROS production.
In order to investigate the functional consequences of
decreased CAIX expression, we assessed hypoxia tolerance.
Survival under prolonged hypoxia for parental and mtDNA
depleted 143B cells was not altered. On the other hand, the
mutant cybrid models rescued the lower survival of the control
cybrid line (Figure 5A). In vivo, MELAS cybrid xenografts
needed longer to reach 500 mm3 compared to control cybrid
tumors, however no differences were found in doubling time
upon tumor establishment suggesting a delayed tumor take
(P = 0.09, Figure 5B). Additionally, the mutation percentage
for the mutant hybrid xenografts at sacrifice was decreased
compared with the injected cells (Figure 5B). HIF-1α protein was
reduced in the mutant hybrid xenografts compared with control
tumors, however a large variation was observed (Figure 5C),
while an increase in hypoxia-inducible factor-2α (HIF-2α)
expression was observed for the mutant xenografts (Figure S7).
Additionally, we observed that in the MELAS cybrids xenografts
pimonidazole-positive hypoxic areas were reduced. However,
no large differences upon CAIX staining could be observed
(Figure 5C).
Alterations in overall mRNA translation are influenced
upstream by the unfolded protein response (UPR), a mechanism
influenced by hypoxia and energetic stress (32–34). Additionally,
there is also a specific mitochondrial UPR response. One of
the regulators influencing this mitochondrial UPR is NAD-
dependent deacetylase sirtuin-3 (SIRT3) (35). SIRT3 is located
in the mitochondria and is involved in various cellular
mechanisms such as nutrient stress (36), fatty acid oxidation
(37), AMPK activation (38), anti-oxidant mechanisms (39) and
in the activation of a hypoxia-induced mitochondrial form
of autophagy (mitophagy) (40). No major hypoxia-induced
differences could be observed for SIRT3 mRNA expression
levels (Figure S8), however MELAS1 showed a reduced SIRT3
expression upon hypoxia.
DISCUSSION
In the present study, the effect of OXPHOS inhibition using
genetic models (mtDNA depleted cells and mtDNA mutated
cytoplasmic hybrids) or pharmacological inhibitors (rotenone or
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FIGURE 5 | Functional consequences of mtDNA mutations in relation to hypoxia. (A) Hypoxia tolerance. Data represents the mean of ≥3 independent biological
repeats ± SEM. (B) Percentage not reaching 500 mm3 (left panel), Doubling time (middle panel), and mutation percentage before injection and after tumor excision
(right panel). (C) Representative Western blot and quantification of HIF-1α protein expression (left). Immunohistochemisty (right) of hypoxia assessed using
pimonidazole (green) and CAIX (red).
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metformin) on CAIX expression and HIF-1α stabilization was
investigated. We hypothesized that a decrease of mitochondrial
respiration through OXPHOS would lead to an increase in CAIX
expression upon hypoxia exposure due to an induced metabolic
shift. However, contradicting our hypothesis we observed that
CAIX expression as well as HIF-1α levels were reduced in cells
with extreme mitochondrial dysfunction, which seems to be
heteroplasmy dependent, when exposed to low (≤0.2 O2) oxygen
tension. We also observed a simultaneous increase of CAXII
expression, which can be a compensation measure for CAIX
down regulation (41). Since the tumor microenvironment is a
heterogeneous and dynamic mechanism, cells within a tumor
can have different gene expression profiles, metabolism and
oxygen supply (42–44). The adaptation of cancer cells to for
example hypoxia is critical for tumor progression and metastasis
formation and is regulated by hypoxia-inducible factor-1 (HIF-1)
(45–48). Under reduced oxygen conditions, normally HIF-1α is
stabilized (2, 49).
Different studies have described an association between
HIF-1 and mitochondrial function. Genetic modulation of
mitochondrial function, both through mtDNA depletion,
mutations and/or nDNA mutations, could potentially serve
as an interesting proof of concept strategy. In our study,
mtDNA variation and depletion indeed showed HIF-1α de-
stabilization. This was confirmed in a recent proof of concept
study in 2 different tumor backgrounds (HCT116 and 143B)
having a nuclear-encoded NDUFS3 knock-out, where HIF-1α
stabilization was abolished, but that tumors were able to re-adapt
to the hypoxia response (50). These adaptations to hypoxia are
supported by the observed increase in HIF-2 expression in the
cybrid mutant xenografts, which also has been evidenced from
our recently published work (21).
Next to genetic alterations to induce impairment of OXPHOS
function and subsequently cause a reduced HIF-1 stabilization,
pharmacological inhibitors are also able to cause this effect.
For instance it has been shown that BAY 87-2243, a potent
inhibitor of HIF-1α, reduced tumor growth, potentially through
targeting mitochondrial complex I (CI) (51, 52). Similarly, the
CI inhibitor Kalkitoxin reduced tumor cell proliferation under
hypoxia, but was also capable of reducing HIF1 stabilization (53).
The CI inhibitor AG311 also reduced HIF-1α stabilization and
in combination with an inhibitor of the pyruvate dehydrogenase
kinase, a key regulatory enzyme of oxidative metabolism, resulted
in a reduced tumor growth (54). The potentially most clinical
interesting CI inhibitor, metformin, also used in our study, has
already shown its ability to decrease HIF-1α stabilization in
various tumor backgrounds (55, 56) and therefore contributes
to a slower tumor growth, potentially related to the suppression
of VEGF (56–58). However, a tumor-dependent effect might be
present as we did not observe reduced levels of CAIX and VEGF
upon metformin exposure in all tumor cell types. This is in
line with findings of Khan et al., that indicate that biguanide-
induced mitochondrial CI dysfunction stabilizes HIF-1α through
mitochondrial ROS signaling in malignant lymphocytes and
responses can vary between tumor types (59).
ROS formation and PHD activity can be ruled out as
modulators for mitochondrial dependent HIF stabilization as
shown here and by others (22, 50, 55). Similar observations have
been made previously in severe mtDNA modulated cell lines,
as well as the non-involvement of total glutathione levels (19),
which also has been observed in fibroblasts from which our
cybrids have been generated (17). In contrast, others indicate
that mitochondrial ROS production is necessary for HIF-1α
stabilization (60), even when a functional OXPHOS is not present
(61). In addition to its role in proliferation, survival, angiogenesis
and metastasis, HIF-1 is also involved in the regulation of tumor
cell metabolism (2, 62, 63).
Our findings show that the time for tumor take was longer
for mutant hybrid xenografts, but growth rates were not
altered once the tumor was established when compared to
control tumors. Previously, it has been shown that HIF-1α is
responsible for tumor establishment, since HIF-1α knockdown
resulted in a longer time needed to reach 60 mm3, while no
differences in tumor growth rate was observed once tumors
were established (64). In agreement, HIF-1α expression levels
were reduced for the mutant hybrid xenografts. Furthermore,
most of the tumors established from the mutant cell line lost
their m.3243A>G mutation in vivo, possibly explaining the
tumor take as we observed. Importantly, repopulation events
in tumors harboring a mtDNA mutation or depletion should
be taken into consideration, which eventually can lead to
activation of the HIF-1 pathway and resulting tumor growth
(65), a phenomenon also observed in our xenograft model. The
presence of HIF-1α in cell lines with lower mutation percentage
supports this observation. Another possible explanation of the
absence of HIF-1α stabilization might be the involvement of
the AMPK-mTOR pathway, which regulates energetic stress
responses under normoxic conditions, as for instance the CI
inhibitor metformin used in our experiments causes inhibition of
mTOR (66, 67). However, additional experiments are necessary
to evaluate if OXPHOS inhibition is inducing alterations
in AMPK-mTOR signaling resulting in the observed HIF-1α
deregulation by altered mRNA translation. Alterations in general
mRNA translation are influenced upstream by the unfolded
protein response (UPR), a mechanism influenced by hypoxia
and energetic stress (32–34), but also these relationships need
further investigations.
CONCLUSIONS
This study explored the influence of mitochondrial function
in the regulation of CAIX expression. The induction of
mitochondrial dysfunction, by either depletion or by point
mutations causing a severe mitochondrial phenotype, or
inhibition of CI leads to a decreased CAIX expression. In our
study, we observed in a MELAS cybrid model (m.3243A>G
encoding for MT-TL1) that indeed CAIX mRNA and protein
expressionwas reduced under hypoxic conditions. These findings
suggest a general mitochondrial mechanism independent of its
origin (either mtDNA of nDNA) of the mitochondrial gene
(19, 50). Although the data on CI pharmacological inhibition
were not always as clear as for the genetic cellular models,
the differences in effects could probably be explained by cell
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type dependent differences. Here, similar results were observed
for another HIF-1α target, VEGF caused by a reduced HIF-
1α stabilization. Potentially this reduced HIF-1α stabilization
phenotype can lead to a reduced tumor take in vivo however the
precise underlying mechanisms should be further elucidated.
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Supplementary Figure S5 | CAXII mRNA expression. Left panel: CAXII mRNA
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CAXII mRNA expression for levels for cybrid (m.3243 A>G mutant) cells and
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N = 2; Mean + SEM.
Supplementary Figure S6 | ROS production. Top panel: ROS levels for 143B
parental and 143B ρ0 cells upon normoxia and hypoxia. Bottom panel: ROS
levels for cybrid (m.3243 A>G mutant) cells and control cells upon normoxia and
hypoxia. Data are normalized to untreated (–) normoxia levels of either parental or
control 1 cells. R = rotenone, M = metformin. N = 3; Mean + SEM.
Supplementary Figure S7 | HIF-2 protein expression Left panel: Representative
Western blot of HIF-2 expression in xenografts harboring a m.3243A>G mutation
Right panel: quantification of HIF-2 protein expression normalized to actin levels.
Supplementary Figure S8 | SIRT3 mRNA expression upon normoxia (gray) and
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panal). Data represent the mean + SEM of three biological repeats. ∗p < 0.05.
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